Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PROSTVAC-V (Vaccinia)/TRICOM Clear all

Conditions: Prostate Cancer
Interventions: Sargramostim (GM-CSF, Leukine), Flutamide (Eulexin), PROSTVAC-F/ TRICOM, PROSTVAC-V/TRICOM; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 110 Years · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 3
States / cities: Bethesda, Maryland • New Brunswick, New Jersey • Philadelphia, Pennsylvania

Conditions: Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
Interventions: Laboratory Biomarker Analysis, Placebo Administration, Rilimogene Galvacirepvec; Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Male only
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 7
States / cities: Los Angeles, California • Newport Beach, California • Orange, California + 3 more

Conditions: Prostate Cancer
Interventions: PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -F/TRICOM, PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM, Enzalutamide; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer, Prostatic Neoplasms, Neoplasms, Prostate
Interventions: PROSTVAC-V/TRICOM, PROSTVAC-F/TRICOM; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostatic Neoplasms
Interventions: Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM), Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM), Recombinant Fowlpox-GM-CSF; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostatic Neoplasms
Interventions: Recombinant Fowlpox-GM-CSF, Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM), Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM), Recombinant Human GM-CSF; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Prostate Carcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions: Bicalutamide, Goserelin Acetate, Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine, Recombinant Vaccinia-TRICOM Vaccine, Sargramostim; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 7
States / cities: Jacksonville, Florida • Chicago, Illinois • Indianapolis, Indiana + 3 more

Conditions: Prostate Cancer
Interventions: PROSTVAC-V/F, Nivolumab, Prostatectomy, Biopsy, Tylenol; Biological · Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Hormone-Sensitive Prostate Cancer
Interventions: PROSTVAC-V, PROSTVAC-F, Nivolumab, Ipilimumab, Neoantigen DNA vaccine, TriGrid Delivery System, Tumor biopsy, Peripheral blood, Fecal samples, Leukapheresis; Biological · Drug · Device + 1 more
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Docetaxel, Laboratory Biomarker Analysis, Prednisone, Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine, Rilimogene Galvacirepvec; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 14
States / cities: Jacksonville, Florida • Chicago, Illinois • Highland Park, Illinois + 10 more

Conditions: Prostate Cancer
Interventions: PROSTVAC-F (Fowlpox)/TRICOM, PROSTVAC-V (Vaccinia)/TRICOM, Enzalutamide (Xtandi); Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer

PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer

Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy

A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy

Sequential Vaccinations in Prostate Cancer Patients

A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer